CONCOR TABLET 2.5 mg

국가: 싱가포르

언어: 영어

출처: HSA (Health Sciences Authority)

유효 성분:

BISOPROLOL FUMARATE

제공처:

MERCK PTE. LTD.

ATC 코드:

C07AB07

복용량:

2.5 mg

약제 형태:

TABLET, FILM COATED

구성:

BISOPROLOL FUMARATE 2.5 mg

관리 경로:

ORAL

처방전 유형:

Prescription Only

Manufactured by:

Merck Healthcare KGaA

승인 상태:

ACTIVE

승인 날짜:

2000-07-13

환자 정보 전단

Concor 2.5 mg, film-coated tablets
Concor 5 mg, film-coated tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Concor 2.5 mg:
Each tablet contains 2.5 mg bisoprolol fumarate.
Concor 5 mg:
Each tablet contains 5 mg bisoprolol fumarate.
PHARMACEUTICAL FORM
Film-coated tablet.
Concor 2.5 mg:
White, heart-shaped, scored and film-coated tablets.
Concor 5 mg:
Yellowish  white,  heart-shaped,  scored  and  film-coated 
tablets.
CLINICAL PARTICULARS
THERAPEUTIC INDICATIONS
Treatment of hypertension as well as treatment of coronary 
heart disease (angina pectoris).
Treatment of stable chronic heart failure with reduced systolic 
left  ventricular  function  in  addition  to  ACE  inhibitors,  and 
diuretics,  and  optionally  cardiac  glycosides  (for  additional 
information see section Pharmacodynamic properties).
POSOLOGY AND METHOD OF ADMINISTRATION
For all indications
Treatment with bisoprolol is generally a long-term therapy.
Do not stop treatment abruptly or change the recommended 
dose  without  talking  to  your  doctor  first  since  this  might 
lead  to  a  transitory  worsening  of  condition.  Especially  in 
patients  with  ischaemic  heart  disease,  treatment  must  not 
be discontinued suddenly. If discontinuation is necessary, the 
daily dose is gradually decreased.
Concor tablets are taken in the morning with or without food. 
They are swallowed with some liquid and not to be chewed.
Treatment of hypertension or angina pectoris
For both indications the dosage is 5 mg bisoprolol once daily. 
If necessary, the dose may be increased to 10 mg bisoprolol 
once daily.
In all cases the dosage is adjusted individually, in particular 
according to the pulse rate and therapeutic success.
Treatment of stable chronic heart failure
Standard treatment of CHF consists of an ACE inhibitor (or 
an angiotensin receptor blocker in case of 

제품 특성 요약

CONCOR

Bisoprolol fumarate
Concor 2.5 mg, film-coated tablets
Concor 5 mg, film-coated tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Concor 2.5 mg: Each tablet contains 2.5 mg bisoprolol fumarate.
Concor 5 mg: Each tablet contains 5 mg bisoprolol fumarate.
PHARMACEUTICAL FORM
Film-coated tablet.
Concor 2.5 mg: White, heart-shaped, scored and film-coated tablets.
Concor 5 mg: Yellowish white, heart-shaped, scored and film-coated
tablets.
CLINICAL PARTICULARS
THERAPEUTIC INDICATIONS
Treatment of hypertension as well as treatment of coronary heart
disease (angina pectoris).
Treatment of stable chronic heart failure with reduced systolic left
ventricular function in addition
to ACE inhibitors, and diuretics, and optionally cardiac glycosides
(for additional information see
section _Pharmacodynamic properties_).
POSOLOGY AND METHOD OF ADMINISTRATION
For all indications
Treatment with bisoprolol is generally a long-term therapy.
DO NOT STOP TREATMENT ABRUPTLY OR CHANGE THE RECOMMENDED DOSE WITHOUT
TALKING TO YOUR
DOCTOR FIRST since this might lead to a transitory worsening of
condition. Especially in patients
with ischaemic heart disease, treatment must not be discontinued
suddenly. If discontinuation is
necessary, the daily dose is gradually decreased.
Concor tablets are taken in the morning with or without food. They are
swallowed with some
liquid and not to be chewed.
Treatment of hypertension or angina pectoris
For both indications the dosage is 5 mg bisoprolol once daily. If
necessary, the dose may be
increased to 10 mg bisoprolol once daily.
In all cases the dosage is adjusted individually, in particular
according to the pulse rate and
therapeutic success.
Treatment of stable chronic heart failure
Standard treatment of CHF consists of an ACE inhibitor (or an
angiotensin receptor blocker in
case of intolerance to ACE inhibitors), a beta-blocker, diuretics, and
when appropriate cardiac
glycosides. The initiation of treatment of stable chronic heart
failure with Concor necessitates a
special titration phase.